EonArk Raises $14M Seed
EonArk, an AI biotechnology startup, has secured nearly 100 million yuan, equivalent to approximately $14 million, through back-to-back seed and seed+ financing rounds completed within a single month. The company specializes in building AI-native biotechnology platforms, focusing on the intersection of artificial intelligence and life sciences to address complex biological challenges.
Participants in the seed round included Monolith, Boyu Capital, and Nine Chapters Capital. The seed+ round was led by Nine Chapters Capital, with continued participation from Monolith and Boyu Capital, and the addition of Starlink Capital.
The company plans to utilize the fresh capital to support research advancement and team expansion, specifically focusing on the development of its longevity virtual cell platform.
EonArk is led by founder and CEO Si Zhao, who holds a PhD in AI for medicine from Oxford University. The company is focused on the research and development of a longevity virtual cell platform, leveraging specialized AI models for medical and biological applications.
Funding Details
Company Website: https://eonark.ai
Company: EonArk
Raised: $14M
Round: Seed
Funding Date: July 17, 2026
Lead Investor: Nine Chapters Capital
Additional Investors: Monolith, Boyu Capital, Starlink Capital
Software Category: AI Biotechnology